Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Nov;17(10):561-5.
doi: 10.1023/a:1026433813702.

Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol

J Balasch  1 , F Fábregues, M Creus, R Casamitjana, B Puerto, J A Vanrell
Affiliations
Clinical Trial

Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol

J Balasch et al. J Assist Reprod Genet. 2000 Nov.

Abstract

Purpose: The aim was to compare the follicular response to 37.5 and 50 IU of recombinant follicle-stimulating hormone (FSH) as starting doses for ovulation induction in patients with polycystic ovary syndrome (PCOS).

Methods: Prospective, randomized, crossover study including 15 women with clomiphene citrate-resistant chronic anovulatory infertility. Patients were treated with subcutaneous recombinant FSH at starting doses of 37.5 IU and 50 IU, respectively, according to a low-dose step-up protocol. Each woman received both treatments, in a randomized order, with an interval of > or = 1 month between treatments.

Results: All treatment cycles were ovulatory after an appropriate follicular response and hormone levels were similar with both treatments, although the total quantity of FSH required and the mean daily dose required to induce identical follicular development were significantly lower with a starting dose of 37.5 IU FSH. The mean duration of treatment to achieve ovulation was approximately 13 days with both treatments but treatment periods > or = 20 days were required in some patients.

Conclusions: In women with PCOS, a starting dose of 37.5 IU recombinant FSH may be adequate to induce follicular growth. However, the use of low starting doses may result in some cases in increased treatment periods and need for monitoring.

PubMed Disclaimer

References

    1. Franks S, Gilling-Smith C. Advances in induction of ovulation. Curr Opin Obstet Gynecol. 1996;6:136–140. - PubMed
    1. Kettel LM, Hummel WP. Ovulation induction in the estrogenized anovulatory patient. Semin Reprod Endocrinol. 1996;14:309–315. - PubMed
    1. Andoh K, Mizunuma H, Liu X, Kamijo T, Yamada K, Ibuki Y. A comparative study of fixed-dose, step-down, and lowdose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril. 1998;70:840–846. - PubMed
    1. Balasch J, Tur R, Peinado JA. The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: Evidence from a large multicenter study in Spain. J Assist Reprod Genet. 1996;13:551–556. - PubMed
    1. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D, Franks S. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81:3821–3824. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources